Abstract Number: 0694 • ACR Convergence 2025
Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
Background/Purpose: Background/Purpose Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration and progressive, immune-mediated dysfunction of the exocrine glands. Immunoglobulin (Ig)…Abstract Number: 0513 • ACR Convergence 2025
Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
Background/Purpose: While Sjögren’s disease is commonly associated with anti-SSA (anti-Ro) and/or anti-SSB (anti-La) antibodies, these autoantibodies are not disease-specific and may be present in various…Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…Abstract Number: 2491 • ACR Convergence 2025
High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study
Background/Purpose: Anti-Nucleolar Organizer Region 90 (anti-NOR90) antibodies target nucleolar proteins involved in ribosomal RNA transcription and processing, key steps in protein synthesis. These antibodies have…Abstract Number: 2148 • ACR Convergence 2025
Initial MRI Findings as Predictors of Disease Phenotype in Juvenile Dermatomyositis: A Comparative Study of Myositis Specific Antibodies NXP2-Positive and Myositis Specific Antibody-Negative Patients in a Large Tertiary Hospital
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy of childhood, characterized by proximal muscle weakness and distinctive cutaneous findings. Magnetic resonance imaging…Abstract Number: 1693 • ACR Convergence 2025
Characterizing ANCA-specific B Cells in ANCA-associated Vasculitis
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease, characterized by ANCAs targeting myeloperoxidase (MPO) or proteinase-3 (PR3). ANCA-specific B cells have…Abstract Number: 1195 • ACR Convergence 2025
Discordance between Immunoblot and ELISA in the detection of Jo-1 and Ro/Ro-52 Autoantibodies
Background/Purpose: Autoantibodies play a key role in the diagnosis, classification, and prognosis of idiopathic inflammatory myopathies (IIM). Among the most relevant are myositis-specific antibodies (MSAs),…Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…Abstract Number: 0509 • ACR Convergence 2025
Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease characterized by immune-mediated damage to salivary and lacrimal glands. While autoantibodies against muscarinic type 3 receptor…Abstract Number: 0129 • ACR Convergence 2025
Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic thromboinflammatory autoimmune disease characterized by thrombotic or obstetric events occurring in individuals with persistently positive antiphospholipid antibodies (aPL).…Abstract Number: 2484 • ACR Convergence 2025
Phenotype of systemic sclerosis patients with positive anti–NOR-90 antibodies
Background/Purpose: To analyze the clinical associations of anti-Nucleolar Organizer Region 90 antibodies (NOR90) antibodies in patients with systemic sclerosis (SSc)Methods: Cross-sectional study of NOR90-positive SSc…Abstract Number: 2103 • ACR Convergence 2025
PCRX-201 High-Capacity Adenovirus Serotype 5 Gene Therapy Demonstrates Sustained Clinical Efficacy and Safety in Patients With Knee Osteoarthritis
Background/Purpose: Knee OA is a common disease affecting ~15 million people in the United States. There is an urgent unmet need for additional OA treatments…Abstract Number: 1678 • ACR Convergence 2025
Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
Background/Purpose: Clinical trials aimed at delaying or preventing rheumatoid arthritis (RA) in individuals at risk have been published with variable results. In the APIPPRA study,…Abstract Number: 1187 • ACR Convergence 2025
Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Background/Purpose: The associations between various myositis-specific antibodies (MSAs), rapidly progressive interstitial lung disease (RP-ILD), and mortality in antisynthetase syndrome (ASS) have been previously reported in…Abstract Number: 0646 • ACR Convergence 2025
A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
Background/Purpose: Immune reset of autoimmune disease has been proposed to be a potential benefit of T cell engagers (TCEs) and CD19 CAR T therapy. A-319,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 37
- Next Page »